Gestational diabetes mellitus (GDM) — screening, targets & treatment
Bedside summary
GDM is hyperglycaemia detected in pregnancy that is not overt diabetes. Diagnosed by 75 g OGTT at 24-28 weeks (earlier if high risk: prior GDM, BMI >= 30, previous macrosomic baby >= 4.5 kg, first-degree relative with diabetes, high-risk ethnicity incl. South Asian). NICE NG3 diagnostic thresholds: fasting >= 5.6 mmol/L or 2-hour >= 7.8 mmol/L (a single abnormal value diagnoses). Management is tiered: diet/exercise first, then metformin, then insulin. Good glycaemic control reduces fetal and maternal complications. [verify local — WHO/IADPSG thresholds differ; India often uses DIPSI single-step 2-h >= 7.8 mmol/L].
Red flags
- Fasting glucose >= 7.0 at diagnosis or very high HbA1c (likely overt diabetes — fetal anomaly risk, needs urgent control)
- Reduced fetal movements / abnormal CTG
- Rapidly accelerating fetal growth or polyhydramnios (macrosomia -> shoulder dystocia risk)
- Features of pre-eclampsia (BP, proteinuria, symptoms)
- Recurrent hypoglycaemia on treatment
- Ketonuria / symptoms suggesting DKA (rare in GDM, consider overt T1DM)
Assessment
Differential diagnosis
- Pre-existing (overt) type 1 or type 2 diabetes first detected in pregnancy (HbA1c >= 48, random glucose >= 11.1)
- Impaired glucose tolerance
- Stress/steroid-induced hyperglycaemia (e.g. after antenatal corticosteroids)
- MODY (young, strong family history, mild fasting hyperglycaemia)
Investigations
- 75 g OGTT at 24-28 weeks (or booking/early if risk factors, repeat 24-28 wk if normal)
- Diagnostic (NICE NG3): fasting >= 5.6 mmol/L OR 2-h >= 7.8 mmol/L
- HbA1c at booking to exclude pre-existing diabetes (>= 48 mmol/mol = overt)
- Capillary self-monitoring: fasting + 1 h post-meal (or pre-meal) daily once diagnosed
- Growth/liquor ultrasound (serial, for macrosomia/polyhydramnios); fetal surveillance third trimester
- Baseline U&E, consider retinal/renal review if overt diabetes
- Urine for ketones/protein if symptomatic
Management
- Confirm diagnosis on OGTT; distinguish GDM from previously undiagnosed overt diabetes (HbA1c/random glucose)
- Refer to joint diabetes-antenatal clinic within ~1 week; dietitian review
- Start lifestyle: low-glycaemic-index diet, portion control, 30 min daily activity; home glucose monitoring
- Set glycaemic targets: fasting < 5.3; 1-h post-meal < 7.8 (or 2-h post-meal < 6.4) mmol/L; keep > 4 to avoid hypoglycaemia
- If targets not met within 1-2 weeks of lifestyle -> add metformin; add/switch to insulin if still not met or metformin not tolerated/contraindicated
- Immediate insulin (+/- metformin) if fasting glucose >= 7.0 mmol/L at diagnosis, or 6.0-6.9 with macrosomia/polyhydramnios
- Serial growth scans; plan timing/mode of birth (offer birth by 40+6; earlier if complications/macrosomia)
- Intrapartum: monitor maternal glucose hourly, keep 4-7 mmol/L, variable-rate insulin if needed; anticipate shoulder dystocia and neonatal hypoglycaemia
- Postnatal: stop GDM medication after delivery; check fasting glucose/HbA1c at ~6-13 weeks; lifelong annual diabetes screening + lifestyle advice (high future T2DM risk)
Drugs & doses
Disposition
Complications & pitfalls
- Maternal: pre-eclampsia, polyhydramnios, operative/instrumental delivery, future type 2 diabetes
- Fetal/neonatal: macrosomia, shoulder dystocia, birth trauma, neonatal hypoglycaemia, jaundice, respiratory distress
- Stillbirth (poor control)
- Long-term offspring obesity/metabolic risk
Exam pearls
- A single abnormal OGTT value (fasting >= 5.6 or 2-h >= 7.8) diagnoses GDM under NICE.
- Fasting glucose >= 7.0 at diagnosis = go straight to insulin and suspect overt diabetes.
- Antenatal steroids cause a 24-48 h hyperglycaemic spike — pre-empt with extra monitoring/insulin.
- Stop all glucose-lowering drugs immediately after delivery; neonate needs early feeding + glucose checks.
- GDM confers high lifelong T2DM risk — arrange postnatal OGTT/HbA1c and annual screening.
- In India, DIPSI 2-h 75 g >= 7.8 mmol/L (non-fasting) is widely used — confirm local pathway.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.